Akero Therapeutics, Inc.

DB:0K4 Stock Report

Market Cap: €1.9b

Akero Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:0K4 Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
10 Dec 24Sell€82,555William WhiteIndividual2,817€29.31
10 Dec 24Sell€69,396Timothy RolphIndividual2,368€29.31
10 Dec 24Sell€230,198Andrew ChengIndividual7,855€29.31
10 Dec 24Sell€73,353Jonathan YoungIndividual2,503€29.31
10 Dec 24Sell€82,350Catriona YaleIndividual2,810€29.31
10 Dec 24Sell€27,108Patrick LamyIndividual925€29.31
10 Sep 24Sell€41,274Andrew ChengIndividual1,738€23.75
10 Sep 24Sell€12,753Timothy RolphIndividual537€23.75
10 Sep 24Sell€15,175William WhiteIndividual639€23.75
10 Sep 24Sell€15,127Catriona YaleIndividual637€23.75
10 Sep 24Sell€13,489Jonathan YoungIndividual568€23.75
11 Jun 24Sell€166,628Andrew ChengIndividual7,894€21.11
11 Jun 24Sell€50,238Timothy RolphIndividual2,380€21.11
11 Jun 24Sell€12,011Patrick LamyIndividual569€21.11
11 Jun 24Sell€59,755William WhiteIndividual2,831€21.11
11 Jun 24Sell€59,631Catriona YaleIndividual2,825€21.11
11 Jun 24Sell€53,108Jonathan YoungIndividual2,516€21.11
13 Mar 24Sell€16,851Jonathan YoungIndividual651€25.89
13 Mar 24Sell€18,715Catriona YaleIndividual723€25.89
13 Mar 24Sell€18,741William WhiteIndividual724€25.89
13 Mar 24Sell€50,968Andrew ChengIndividual1,969€25.89
13 Mar 24Sell€16,023Timothy RolphIndividual619€25.89

Insider Trading Volume

Insider Buying: 0K4 insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of 0K4?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,207,9821.56%
Public Companies2,525,2523.27%
VC/PE Firms5,233,9896.77%
Hedge Funds5,919,4357.66%
Institutions62,397,01180.7%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 25.3%.

Top Shareholders

Top 25 shareholders own 93.59% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
11.3%
Wellington Management Group LLP
7,896,632€216.8m54.4%0.03%
10.1%
Janus Henderson Group plc
7,077,478€194.3m2.93%0.08%
8.48%
RTW Investments, LP
5,919,435€162.5m8.97%2.44%
8.23%
BlackRock, Inc.
5,747,790€157.8m2.88%no data
7.5%
General Atlantic Service Company, L.P.
5,233,989€143.7m0%2.82%
7.32%
T. Rowe Price Group, Inc.
5,108,455€140.3m-13.6%0.01%
5.27%
The Vanguard Group, Inc.
3,676,581€100.9m-0.77%no data
4%
Alkeon Capital Management, LLC
2,791,437€76.6m-0.08%0.54%
3.62%
Pfizer Inc.
2,525,252€69.3m0%no data
3.59%
State Street Global Advisors, Inc.
2,502,946€68.7m-6.93%no data
2.89%
AllianceBernstein L.P.
2,017,088€55.4m5.73%0.02%
2.46%
Perceptive Advisors LLC
1,714,806€47.1m14.3%1.14%
2.4%
Tavistock Life Sciences
1,676,733€46.0m0%3.33%
2.25%
Geode Capital Management, LLC
1,571,012€43.1m-2.97%no data
1.99%
Redmile Group, LLC
1,387,479€38.1m-14.1%2.25%
1.88%
Point72 Asset Management, L.P.
1,313,361€36.1m0%0.09%
1.57%
Baker Bros. Advisors LP
1,097,082€30.1m0%0.31%
1.35%
Emerald Advisers, LLC
939,628€25.8m-0.06%0.57%
1.34%
Rock Springs Capital Management LP
933,399€25.6m-13.1%0.91%
1.15%
Logos Global Management, L.P.
800,000€22.0m0%2.82%
1.09%
Yiheng Capital Management, L.P.
758,769€20.8m-47.1%3.94%
1.03%
Long Focus Capital Management LLC
719,604€19.8m0%1.82%
0.99%
Deep Track Capital, LP
689,784€18.9m0%0.61%
0.92%
Silverarc Capital Management, LLC
639,840€17.6m2.36%4.28%
0.84%
Northern Trust Global Investments
584,584€16.1m-0.56%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 05:53
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Akero Therapeutics, Inc. is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason ZemanskyBofA Global Research
Alexandria HammondBofA Global Research
Edward NashCanaccord Genuity